AU Patent

AU2023204103B2 — Osmotic dosage forms comprising deutetrabenazine and methods of use thereof

Assigned to Auspex Pharmaceuticals Inc · Expires 2025-08-14 · 1y expired

What this patent protects

#$%^&*AU2023204103B220250814.pdf##### ABSTRACT Provided herein are osmotic dosage forms containing deutetrabenazine for use in the treatment of, e.g., hyperkinetic movement disorders. When orally administered to a subject on a once daily basis, the dosage forms provide a fa…

USPTO Abstract

#$%^&*AU2023204103B220250814.pdf##### ABSTRACT Provided herein are osmotic dosage forms containing deutetrabenazine for use in the treatment of, e.g., hyperkinetic movement disorders. When orally administered to a subject on a once daily basis, the dosage forms provide a favorable pharmacokinetic profile for the active agent indicating treatment efficacy over an extended period of time. Jun 2023 ABSTRACT Provided herein are osmotic dosage forms containing deutetrabenazine for use in the treatment of, e.g., hyperkinetic movement disorders. When orally administered to a subject on a once- daily basis, the dosage forms provide a favorable pharmacokinetic profile for the active agent indicating treatment efficacy over an extended period of time. 2023204103 27

Drugs covered by this patent

Patent Metadata

Patent number
AU2023204103B2
Jurisdiction
AU
Classification
—
Expires
2025-08-14
Drug substance claim
No
Drug product claim
No
Assignee
Auspex Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.